Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma 6Urogenital Neoplasms 5Prostatic Neoplasms 5Prostatic Diseases 5Neoplasms by Site 5Neoplasms 5Male Urogenital Diseases 5Genital Neoplasms, Male 5Genital Diseases, Male 4Transitional Cell Cancer of Renal Pelvis and Ureter 1Lung Neoplasms 1Localized Prostate Cancer 1Genital Diseases 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 112Cisplatin 76Oxaliplatin 44pembrolizumab 34Fluorouracil 32Capecitabine 30durvalumab 27Leucovorin 26lenvatinib 23Magnetic Resonance Spectroscopy 15Irinotecan 14Nivolumab 12Biopsy 12Albumin-Bound Paclitaxel 12tislelizumab 11Specimen Handling 11Radiofrequency Ablation 11Drug Therapy 11pemigatinib 10apatinib 10Taxes 10Floxuridine 10130-nm albumin-bound paclitaxel 10Radiotherapy 9Bevacizumab 9Platinum 8Folfox protocol 8Carboplatin 81,2-diaminocyclohexaneplatinum II citrate 8tremelimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cholangiocarcinoma × padeliporfin × Clear all
NCT00975039 2016-04-18

Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma

Steba Biotech S.A.

Phase 2 Terminated
8 enrolled
Gastrointestinal

Carcinoma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡